Evidence map›Paper›PMID 40813865›Full record

ArticleTranslational psychiatry2025

Differentiating biomarker features and familial characteristics of B-SNIP psychosis Biotypes.

David A Parker, Rebekah L Trotti, Jennifer E McDowell, Sarah K Keedy, Matcheri S Keshavan, Godfrey D Pearlson, Elliot S Gershon, Elena I Ivleva, Ling-Yu Huang, Kodiak Sauer and 4 more

Abstract read
In one paragraph

Article in Translational psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. The breakthrough discoveries for thriving with bipolar disorder (BDInternational journal of bipolar disorders · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

David A ParkerDepartments of Psychology and Neuroscience, BioImaging Research Center, University of Georgia, Athens, GA, USA. David.a.parker@emory.edu.ORCID http://orcid.org/0000-0002-0240-4741
Rebekah L TrottiDepartments of Psychology and Neuroscience, BioImaging Research Center, University of Georgia, Athens, GA, USA.ORCID http://orcid.org/0000-0003-4660-5219
Jennifer E McDowellDepartments of Psychology and Neuroscience, BioImaging Research Center, University of Georgia, Athens, GA, USA.ORCID http://orcid.org/0000-0001-8134-3678
Sarah K KeedyDepartment of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL, USA.ORCID http://orcid.org/0000-0002-2139-9271
Matcheri S KeshavanDepartment of Psychiatry, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5945-888X
Godfrey D PearlsonDepartments of Psychiatry and Neuroscience, Yale University School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0002-7525-5185
Elliot S GershonDepartment of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL, USA.ORCID http://orcid.org/0000-0003-4818-8631
Elena I IvlevaDepartment of Psychiatry, UT Southwestern Medical Center, Dallas, TX, USA.
Ling-Yu HuangDepartments of Psychology and Neuroscience, BioImaging Research Center, University of Georgia, Athens, GA, USA.ORCID http://orcid.org/0000-0002-7653-8590
Kodiak SauerDepartment of Political Science, Princeton University, Princeton, NJ, USA.ORCID http://orcid.org/0009-0001-7149-8294
S Kristian HillDepartment of Psychology, Rosalind Franklin University of Medicine and Science, Chicago, IL, USA.
John A SweeneyDepartment of Psychiatry and Behavioral Neuroscience, University of Cincinnati, Cincinnati, OH, USA.
Carol A TammingaDepartment of Psychiatry, UT Southwestern Medical Center, Dallas, TX, USA.ORCID http://orcid.org/0000-0002-6366-5697
Brett A ClementzDepartments of Psychology and Neuroscience, BioImaging Research Center, University of Georgia, Athens, GA, USA. clementz@uga.edu.ORCID http://orcid.org/0000-0002-2563-9594

Funding

Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE)UL1TR002378 · NCATS · EMORY UNIVERSITY · PI Andres J Garcia, Elizabeth O. Ofili · 2017 to 2026
$92.1M
J: NRSA Training CoreTL1TR002382 · NCATS · EMORY UNIVERSITY · PI HENRY M BLUMBERG, Vasiliki Michopoulos · 2017 to 2026
$8.5M
Bipolar & Schizophrenia Consortium for Parsing Intermediate PhenotypesR01MH077851 · NIMH · UT SOUTHWESTERN MEDICAL CENTER · PI TAMMINGA, CAROL A · 2007 to 2019
$7.8M
Bipolar & Schizophrenia Consortium for Parsing Intermediate PhenotypesR01MH077945 · NIMH · YALE UNIVERSITY · PI PEARLSON, GODFREY D · 2007 to 2019
$7.6M
Stability of Biotypes: a Longitudinal EvaluationR01MH078113 · NIMH · WAYNE STATE UNIVERSITY · PI KESHAVAN, MATCHERI S. · 2007 to 2019
$6.2M
Stability of Biotypes: a Longitudinal Evaluation (STABLE)R01MH103368 · NIMH · UNIVERSITY OF CHICAGO · PI GERSHON, ELLIOT S, KEEDY, SARAH K · 2015 to 2019
$4.5M
5/5 BIPOLAR-SCHIZOPHRENIA NETWORK FOR INTERMEDIATE PHENOTYPES (B-SNIP) - Resubmission - 1R01MH103366 · NIMH · UNIVERSITY OF GEORGIA · PI CLEMENTZ, BRETT A, GIBBONS, ROBERT D · 2015 to 2019
$3.8M
1/5 - Selective Antipsychotic Response to Clozapine in B-SNIP Biotype-1 (Clozapine)R01MH124813 · NIMH · UT SOUTHWESTERN MEDICAL CENTER · PI TAMMINGA, CAROL A · 2021 to 2025
$1.8M
2/5-Clozapine Response and Biomarker Correlates in Low-IEA Biotype-1R01MH124804 · NIMH · UNIVERSITY OF CHICAGO · PI GERSHON, ELLIOT S, KEEDY, SARAH K · 2021 to 2025
$1.8M
3/5 Selective Antipsychotic Response to Clozapine in B-SNIP Biotype-1 (CLOZAPINE)R01MH124802 · NIMH · YALE UNIVERSITY · PI PEARLSON, GODFREY D · 2021 to 2025
$1.8M
5/5: Selective Antipsychotic Response to Clozapine in B-SNIP Biotype-1 (CLOZAPINE)R01MH124803 · NIMH · UNIVERSITY OF GEORGIA · PI CLEMENTZ, BRETT A · 2021 to 2025
$1.6M
2/5 Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services (BICEPS)R01MH127162 · NIMH · UNIVERSITY OF CHICAGO · PI Elliot S Gershon, Sarah K Keedy · 2022 to 2026
$1.5M
NCATS NIH HHS TL1 TR002382NCATS NIH HHS UL1 TR002378NIMH NIH HHS R01 MH077851NIMH NIH HHS R01 MH077945NIMH NIH HHS R01 MH078113NIMH NIH HHS R01 MH096900NIMH NIH HHS R01 MH096913NIMH NIH HHS R01 MH096942NIMH NIH HHS R01 MH096957NIMH NIH HHS R01 MH103366NIMH NIH HHS R01 MH103368NIMH NIH HHS R01 MH124802NIMH NIH HHS R01 MH124803NIMH NIH HHS R01 MH124804NIMH NIH HHS R01 MH124806NIMH NIH HHS R01 MH124807NIMH NIH HHS R01 MH124813NIMH NIH HHS R01 MH127158NIMH NIH HHS R01 MH127162NIMH NIH HHS R01 MH127174NIMH NIH HHS R01 MH127179NIMH NIH HHS R21 MH126398U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (NCATS) TL1TR002382U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (NCATS) UL1TR002378U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) MH077851U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) MH077945U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) MH078113U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) MH096900U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) MH096913U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) MH096942U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) MH096957U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) MH103366U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) MH103368U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) MH124802U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) MH124803U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) MH124804U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) MH124806U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) MH124807U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) MH124813U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) MH126398U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) MH127158U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) MH127162U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) MH127174U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) MH127179
6 · The paper itself

Abstract

Idiopathic psychosis shows considerable biological heterogeneity across cases. The Bipolar-Schizophrenia Network for Intermediate Phenotypes (B-SNIP) used psychosis-relevant biomarkers to identify psychosis Biotypes, which will aid etiological and targeted treatment investigations. Here, our previous approach (Clementz et al. 2022) is updated, which supports the development of an efficient psychosis Biotype diagnostic procedure called ADEPT. Psychosis probands (n = 1907), their first-degree biological relatives (n = 705), and healthy participants (n = 895) completed a biomarker battery composed of cognitive performance, saccades, and auditory EEG/ERP measurements. EEG and ERP quantifications were modified from previous Biotypes iterations. Multivariate integration using multiple approaches reduced biomarker outcomes to 11 "bio-factors." Twenty-four different approaches indicated bio-factor data among probands were best described by three subgroups. Numerical taxonomy with k-means clustering yielded psychosis Biotypes; Rand Indices evaluated individual-case consistency of Biotype assignments. Psychosis subgroups, their non-psychotic first-degree relatives, and healthy individuals were compared across bio-factors. The three psychosis Biotypes differed significantly on all 11 bio-factors, especially prominent for general cognition, antisaccades, ERP magnitude, and intrinsic neural activity. Rand Indices showed excellent individual-case consistency of Biotype membership when samples included more than 1000 subjects. Canonical discriminant analysis described composite bio-factors that simplified group comparisons: "Pattern-2" (high antisaccade errors, low BACS, high ongoing EEG) captured Biotype-2, "Pattern-1" (low ERP amplitudes, low intrinsic EEG) captured Biotype-1, and "Pattern-3" (low frontal P3 complex, accentuated S2 ERP, faster saccadic reaction times) captured Biotype-3. First-degree relatives had patterns like their proband for general cognition, antisaccades, ERP magnitudes, and intrinsic brain activity. These outcomes refine and extend operations for characterizing biologically distinct psychosis Biotypes. They also show that over 1000 observations are useful for achieving consistent individual-case diagnostic assignments. First-degree relative data implicate specific bio-factors as familial within idiopathic psychosis which may inform genetic studies.

Indexed as

Psychotic DisordersSchizophreniaAdolescentAdultBiomarkersElectroencephalographyEvoked PotentialsFamilyFemaleHumansMaleMiddle AgedPhenotypeSaccadesYoung AdultBiomarkers

Identifiers

PMID40813865
PMCPMC12354876

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.